{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T03:09:49Z","timestamp":1779246589921,"version":"3.51.4"},"reference-count":52,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T00:00:00Z","timestamp":1737849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T00:00:00Z","timestamp":1737849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Cognivue\n                      <jats:italic toggle=\"yes\">Clarity<\/jats:italic>\n                      <jats:sup>\u00ae<\/jats:sup>\n                      is an FDA-cleared computerized cognitive test to screen for cognitive impairment included in the Bio-Hermes Study to test blood-based and digital biomarkers\u2019 ability to screen for mild cognitive impairment (MCI) and Alzheimer's disease (AD). A subset of cognitively normal individuals have amyloid deposition (Preclinical AD) but no current assessment can identify these individuals in the absence of expensive biomarkers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      We examined differences in Cognivue\n                      <jats:italic toggle=\"yes\">Clarity<\/jats:italic>\n                      performance between amyloid positive and amyloid negative individuals and whether Cognivue\n                      <jats:italic toggle=\"yes\">Clarity<\/jats:italic>\n                      could differentiate True Controls (cognitively normal\/amyloid negative), Preclinical AD (cognitively normal\/amyloid positive), and MCI due to AD (MCI-AD, cognitively impaired\/amyloid positive).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Cognivue\n                      <jats:italic toggle=\"yes\">Clarity<\/jats:italic>\n                      was administered to all participants in the Bio-Hermes Study who also had amyloid PET and blood-based biomarkers. Performance was compared between biomarker-defined groups: True Controls (n\u2009=\u2009297), Preclinical AD (n\u2009=\u200995), and MCI-AD (n\u2009=\u2009113).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Cognivue\n                      <jats:italic toggle=\"yes\">Clarity<\/jats:italic>\n                      global scores distinguished amyloid positive individuals from amyloid negative individuals (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and differentiated True Controls versus Preclinical AD (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.014) and Preclinical AD versus MCI-AD (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Three subtests [Shape Discrimination (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.004), Visual Salience (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.008), Adaptive Motor Control (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.004)] and the 3-test mean (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001) differentiated True Controls from Preclinical AD. The 3-test composite correlated with Amyloid PET (r\u2009=\u2009\u22120.433) and pTau217 (r\u2009=\u2009\u22120.400). The 3-test mean identified Preclinical AD in both White and Black participants.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Cognivue\n                      <jats:italic toggle=\"yes\">Clarity<\/jats:italic>\n                      , a 10-min computerized battery, screens for individuals with cognitive impairment, characterizes amyloid positive individuals, and identifies Preclinical AD. This has great potential as a cost- and time-effective strategy to screen and enroll in AD prevention trials.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13872877251314117","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T12:50:09Z","timestamp":1738155009000},"page":"83-94","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Cognivue\n                    <i>Clarity<\/i>\n                    <sup>\u00ae<\/sup>\n                    characterizes amyloid status and preclinical Alzheimer's disease in biomarker confirmed cohorts in the Bio-Hermes Study"],"prefix":"10.1177","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5678-245X","authenticated-orcid":false,"given":"James E","family":"Galvin","sequence":"first","affiliation":[{"name":"Comprehensive Center for Brain Health, Department of Neurology, University of Miami Miller School of Medicine, Boca Raton, FL, USA"},{"name":"Cognivue, Inc., Victor, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J","family":"Kleiman","sequence":"additional","affiliation":[{"name":"Comprehensive Center for Brain Health, Department of Neurology, University of Miami Miller School of Medicine, Boca Raton, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul W","family":"Estes","sequence":"additional","affiliation":[{"name":"Cognivue, Inc., Victor, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather M","family":"Harris","sequence":"additional","affiliation":[{"name":"Cognivue, Inc., Victor, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernest","family":"Fung","sequence":"additional","affiliation":[{"name":"Cognivue, Inc., Victor, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,1,26]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13809"},{"key":"e_1_3_4_3_2","unstructured":"Dementia statistics. Alzheimer Disease International https:\/\/www.alzint.org\/about\/dementia-facts-figures\/dementia-statistics\/ (2024 accessed on 22 June 2024)."},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.131"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.960648"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-240007"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26838"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011599"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13722"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-240331"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-75304-5"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12748"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305032"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.003"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/13803395.2019.1593949"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2014.803"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.008"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.005"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-4679(198405)40:3<785::AID-JCLP2270400325>3.0.CO;2-4"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/geronj\/37.3.323"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2021.05.011"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-021-00234-5"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.4201"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13764"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05784-y"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2018.04.022"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_3_4_30_2","first-page":"1226","article-title":"ETDRS-fast: implementing psychophysical adaptive methods to standardized visual acuity measurement with ETDRS charts","volume":"42","author":"Camparini M","year":"2021","unstructured":"Camparini M, Cassinari P, Ferrigno L, et al. ETDRS-fast: implementing psychophysical adaptive methods to standardized visual acuity measurement with ETDRS charts. Invest Ophthalmol Vis Sci 2021; 42: 1226\u20131231.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.5498\/wjp.v10.i1.1"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.5498\/wjp.v11.i7.265"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.4300\/JGME-D-12-00156.1"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.5.758"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.883131"},{"key":"e_1_3_4_36_2","first-page":"668","article-title":"Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: the PACC5","volume":"3","author":"Papp KV","year":"2017","unstructured":"Papp KV, Rentz DM, Orlovsky I, et al. Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: the PACC5. Alzheimers Dement 2017; 3: 668\u2013677.","journal-title":"Alzheimers Dement"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.17"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13774"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2020.38"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22195-z"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.3390\/ani14111577"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.3390\/jintelligence12050050"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2024.1359874"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.3390\/ani13142326"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1010919108"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-2236(83)90190-X"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/hbm.26162"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.194720"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01249-0"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcad057"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.5319"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-220891"}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877251314117","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13872877251314117","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877251314117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:09:43Z","timestamp":1777370983000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13872877251314117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,26]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1177\/13872877251314117"],"URL":"https:\/\/doi.org\/10.1177\/13872877251314117","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,26]]}}}